Events

View All
    Join BIOCYTOGEN at LSE Vanderbilt University

    Join BIOCYTOGEN at LSE Vanderbilt University

    April 07, 2026
    Share on:

    We are excited to be attending the Life Science Exhibits (LSE) vendor show at Vanderbilt University on April 7th. Come visit our booth to grab some swag and meet the Biocytogen team! We’ll be sharing our latest research studies, drug development insights, and advanced mouse models that are driving progress across the biotech landscape.

    What is LSE? 

    The Life Science Exhibits (LSE) is a premier event planning company hosting Research Supplier Product Shows across the U.S. With over 20 years of experience and more than 100 annual events, LSE connects vendors with researchers at top institutions, offering access to the latest products, reagents, and equipment. 

    Event Overview  

    Date: April 7th, 2026

    Venue: Vanderbilt University, Holiday Inn Nashville-Vanderbilt, 1st Floor, 2613 West End Avenue, Nashville, TN 37203

    Event Schedule  

    For more information about the LSE vendor show, please visit their website here

    About BIOCYTOGEN

    Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com. 

    We look forward to meeting you in Nashville, Tennessee!